Cancer is among the top life threatening health conditions in the world. While there is currently no cure for cancer, scientists are still determined to treatments that prolong life and make it easier for the victims. One of the renowned personalities in the fight against cancer is one Dr. Clay Siegall. Dr. Clay serves as the CEO of Seattle Genetics and has dedicated his life and career towards improving the conditions of cancer patients. Dr Siegall co-founded Seattle Genetics in 1998 and has ever since worked adamantly to ensure the organization makes significant developments in cancer research.
After earning a Genetics Ph.D. from George Washington University, Siegall launched his career as a research investigator for Bristol-Myers Squibb Pharmaceutical Research Institute. He got promoted as principal scientist and later became the National Cancer Institute’s Staff Fellow and Biotechnology Fellow. It is after this that Siegall helped in the launching of Seattle Genetics.
Siegall’s Role in Seattle Genetics
The core of Siegall’s achievements has been a focus on important research and the implementation of cutting edge research projects. His motivation has been the genuine desire to assist patients and relief them of their suffering. It is due to his passion that Seattle Genetics has moved to incredible heights in cancer research. For example, it is through Dr. Siegall’s leadership that Seattle Genetics was able to come up with antibody-drug conjugates also known as ADCs, the first of their kind in the history of cancer research. Siegall facilitated the development of ADCETRIS, a FDA approved drug for cancer treatment. Since its approval in 2011, ADCETRIS has been embraced worldwide, and is now utilized in over 60 countries worldwide.
Siegall’s Contribution to the Cancer Research Community
Siegall currently has 15 patents and has not relented in his search for new methods of advancing the research on cancer. He has contributed to the research community by publishing new research discoveries and methods. He has over 70 publications to his name and still continues to share his knowledge with the medical and scientific communities. He is also a significant member of the editorial committees of three influential scientific journals that promote the work of budding scientists who are as determined as himself to end the suffering of cancer patients.